Luminex
We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, flow cytometry and imaging, genomic and proteomic research, and food safety.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
$1.8b Valuation: $1.8b 4.1x EV/Revenue 20.4x EV/EBITDA | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 3 % | 6 % | 24 % | 15 % | 9 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | 20 % | 17 % | 5 % | 17 % | 20 % | 18 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | 6 % | (1 %) | 4 % | 10 % | 10 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 14 % | 14 % | 16 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Luminex Corporation, founded in 1995 and now a part of DiaSorin, operates within the life sciences and clinical diagnostics sectors, providing biological testing technologies. The company's foundational xMAP Technology is a versatile platform based on color-coded microspheres, or beads, that allows for the simultaneous measurement of up to 500 different analytes from a single small sample. This multiplexing capability is central to its product offerings, enabling laboratories to conduct a wide array of tests efficiently.
The company serves a diverse client base that includes clinical diagnostics laboratories, pharmaceutical companies engaged in drug discovery, and researchers in the biomedical, genomic, and proteomic fields. Luminex generates revenue through a multi-faceted business model that includes the sale of its testing systems, such as the MAGPIX, Luminex 200, and FLEXMAP 3D instruments, as well as the licensing of its xMAP technology to a network of partners who then develop and sell their own test kits. Additionally, a significant portion of its income is derived from the sale of consumable bead-based assays and royalty payments from its licensees.
A key milestone in the company's history was its acquisition by DiaSorin, an Italian biotechnology company, in a transaction valued at approximately $1.8 billion, which was completed in July 2021. This event integrated Luminex's multiplexing and molecular diagnostics technologies with DiaSorin's existing immunodiagnostics and molecular diagnostics portfolio, aiming to create a more comprehensive offering for the global diagnostics market. Following the acquisition, Luminex continues to operate under its brand but as a wholly-owned subsidiary of DiaSorin, contributing its expertise in bead-based multiplexing to the parent company's broader strategic goals.
Keywords: clinical diagnostics, life sciences, biological testing, multiplexing technology, xMAP technology, molecular diagnostics, bead-based assays, lab automation, DiaSorin subsidiary, proteomic research
Tech stack
Investments by Luminex
Edit
